RBM39 and acute myeloid leukemia: We then investigated RBM39 expression patterns in AML patients via the Sangerbox web tool (a bioinformatics data analysis platform) via The Cancer Genome Atlas (TCGA) database, which revealed increased RBM39 expression in AML samples compared with normal samples (Fig. S2A, B), and high RBM39 expression was correlated with an unfavorable prognosis in AML patients (Fig. S2C).